Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA5A | P35218 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.48 |
| ▸ | CA6 | P23280 | 2/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271015 | 0.94 | TSHR (0.70) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL18427873 | 0.93 | TSHR (0.65) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL12725076 | 0.93 | TSHR (0.65) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL5523365 | 0.90 | TSHR (0.73) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL12509908 | 0.90 | TSHR (0.73) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL15269927 | 0.88 | TSHR (0.61) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL15269929 | 0.88 | TSHR (0.61) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL12425655 | 0.88 | TSHR (0.70) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL12510088 | 0.88 | TSHR (0.70) | TSHRPTPN1LMNAKMT2ACA12 | |
| SCHEMBL2962132 | 0.88 | TSHR (0.70) | TSHRPTPN1LMNAKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919598-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | TSHR 1697/4885PTPN1 576/4885LMNA 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.